AMGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Amgen Inc (AMGN) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, recent regulatory approval for UPLIZNA, and positive growth outlook outweigh the insider selling and neutral hedge fund sentiment. The stock's technical indicators and analyst ratings also support a long-term investment decision.
The technical indicators for AMGN are overall bullish. The MACD is positive and contracting, indicating upward momentum. The RSI is neutral at 57.087, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support and resistance levels are well-defined, with the stock trading above the pivot point of 361.621, suggesting potential for further upside.
UPLIZNA approval by the European Commission for generalized myasthenia gravis, expanding market potential.
Strong Q4 financial performance with revenue up 8.58% YoY and net income up 112.60% YoY.
Positive analyst ratings and price target increases, with several firms highlighting long-term growth potential.
Significant insider selling, with a 876.66% increase in the last month.
Neutral hedge fund sentiment, indicating a lack of strong institutional buying activity.
Concerns around LOE (Loss of Exclusivity) and competitive pricing risks for key drugs like Repatha.
Amgen delivered strong financial results in Q4 2025. Revenue increased by 8.58% YoY to $9.87 billion, net income surged by 112.60% YoY to $1.33 billion, and EPS rose by 111.21% YoY to $2.45. Gross margin improved significantly to 81.86%, up 24.50% YoY, showcasing robust profitability.
Analyst sentiment is mixed but leans positive. Recent upgrades and price target increases highlight strong Q4 results and long-term growth potential. Notable ratings include TD Cowen's Buy with a $420 target and RBC Capital's Outperform with a $360 target. However, Bernstein downgraded the stock to Market Perform, citing 2026 as a 'waiting year' for MariTide and competitive risks.
